Gamal Eldein Fathy Abd-Ellatef

Author

Also Known As

Gamal E.F. Abd-Ellatef, Gamal Eldein Abd-elrahman, Gamal Eldein F. Abd-Ellatef, Gamal Eldein Fathy Abd-Ellatef, Gamal Eldein Fathy Abd-ellatef, Gamal Eldein Fathy Abd-ellatef Abd-elrahman, Gamal-Eldein Fathy Abd-Ellatef

Publications

359

Citations

H-Index

Concepts

All Affiliations

University of Turin National Research Centre Cairo University

About

Gamal Eldein Fathy Abd-Ellatef is an author at University of Turin specializing in tumor biology, breast cancer, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	150
2	Pharmacology	2	2	150
3	Biomolecular Engineering	1	1	28
4	Cancer Cell Biology	1	1	122
5	Cancer Therapeutics	1	1	28

Gamal Eldein Fathy Abd-Ellatef

Publications

313

Citations

H-Index

Page 1

	Year	Citations
Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells Gamal Eldein Fathy Abd-Ellatef, Elena Gazzano, Daniela Chirio, Pharmaceutics NanomedicineDrug TargetingNanotherapeuticsProtein NanoparticlesPolymer-drug Conjugate	2020	122
<em>Ulva lactuca</em> polysaccharides prevent Wistar rat breast carcinogenesis through the augmentation of apoptosis, enhancement of antioxidant defense system, and suppression of inflammation Gamal Eldein Fathy Abd-Ellatef, Osama M. Ahmed, Eman S. Abdel-Reheim, Breast Cancer Targets and Therapy	2017	75
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer Iris C. Salaroglio, Elena Gazzano, Ahmad Abdullrahman, Journal of Experimental & Clinical Cancer Research	2018	45
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance Konstantin Chegaev, Aurore Fraix, Elena Gazzano, ACS Medicinal Chemistry Letters	2017	43
Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein Gamal Eldein Fathy Abd-Ellatef, Elena Gazzano, Ahmed H. El‐Desoky, Pharmacological Research Breast OncologyOncologyDoxorubicin ResistanceMedicineCancer Biology	2021	28

Page 1